Ming-Jun Tsai
China Medical University, Taiwan
Title: Development of temperature-sensitive PEGylated nanostructured lipid carrier for co-delivery of gemcitabine and Baicalein against A549 cell line
Biography
Biography: Ming-Jun Tsai
Abstract
Gemcitabine hydrochloride is a nucleoside analog that phosphorylated by deoxycytidine kinase to active from inhibiting cellular DNA synthesis. It is widely used to treat solid tumors including colon, lung, pancreatic, breast, bladder and ovarian cancers. Baicalein (5,6,7-trihydroxyflavone) is a flavonoid derived from the root of Scutellaria Baicalensis Georgi, a medicinal plant traditionally used in Asian medicine. Baicalein is well known as a 12/15-lipoxygenase and Xanthine oxidase inhibitor for treatment of inflammation, hypertension, cardiovascular diseases, neuronal cell damage and bacterial infections. This study was designed to investigate whether combination therapy with gemitabine hydrochloride and baicalein enhances antitumor efficacy in A549 cell line. In cytotoxicity study, we found combined gemcitabine hydrochloride and baicalein on A549 cell line showed low IC50 that implied gemcitabine hydrochloride and baicalein might display synergistic antitumor effect. In order to co-delivery gemcitabine hydrochloride and baicalein simultaneously to cancer cell, we used nanostructure lipid carrier as drug vehicle and added functional moieties to increase antitumor efficacy. The results showed that the E.E.% of gemcitabine hydrochloride and baicalein was increased by added vitamin E in the formulation. The average size of carrier was decreased by PEG-25 stearate added. In the cell uptaken by A549 cell line, the formulation with the multi-functional modified had better tumor inhibition than the original formulation.
